Real-World Experience With Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma.

Scott W StrumSeth ClimansVictoria PurcellMorgan BlackEric WinquistScott Ernst

Published in: Journal of cutaneous medicine and surgery (2024)

The 12 month estimates of OS and PFS were lower than pivotal phase I and II clinical trials. However, toxicity was tolerable. Cemiplimab remains a safe and effective therapy in patients with refractory LA and metastatic cSCC disease.

Keyphrases

squamous cell carcinoma
clinical trial
small cell lung cancer
locally advanced
lymph node metastasis
oxidative stress
phase ii
stem cells
randomized controlled trial
mesenchymal stem cells
open label
phase iii
smoking cessation
rectal cancer